|
| | Cyclopenthiazide Basic information |
| | Cyclopenthiazide Chemical Properties |
| Toxicity | LD50 in rats, mice (mg/kg): 141.8 ±24, 232.4 ±25 i.v. (Barrett) |
| | Cyclopenthiazide Usage And Synthesis |
| Uses | Cyclopenthiazide is a thiazide diuretic. Cyclopenthiazide is used in the treatment of oedema caused by conditions such as kidney disease, liver cirrhosis and pre-menstrual syndrome as well as in the treatment of hypertension. | | Uses | Antihypertensive;Sodium Chloride Symporter Inhibitor | | Definition | ChEBI: 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide is a benzothiadiazine. | | World Health Organization (WHO) | Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It
continues to be used mainly in combination drugs. | | Clinical Use | Thiazide diuretic:
Hypertension
Heart failure
Oedema | | Drug interactions | Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with
NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased
cardiac toxicity; effects of lidocaine and mexiletine
antagonised.
Antibacterials: avoid administration with
lymecycline.
Antidepressants: increased risk of hypokalaemia
with reboxetine; enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antiepileptics: increased risk of hyponatraemia with
carbamazepine.
Antifungals: increased risk of hypokalaemia with
amphotericin.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia
increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk
of ventricular arrhythmias with amisulpride;
enhanced hypotensive effect with phenothiazines;
hypokalaemia increases risk of ventricular
arrhythmias with pimozide - avoid.
Atomoxetine: hypokalaemia increases risk of
ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia
occurs.
Ciclosporin: increased risk of nephrotoxicity and
possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias
due to hypokalaemia with arsenic trioxide; increased
risk of nephrotoxicity and ototoxicity with platinum
compounds.
Lithium: excretion reduced, increased toxicity | | Metabolism | Cyclopenthiazide appears to be entirely excreted
unchanged in the urine. |
| | Cyclopenthiazide Preparation Products And Raw materials |
|
